Jim, Good summary of the past 3 years.
Cal, I don't think these new rules would have helped us, during that time. What do you think?
Cal posted short time ago ('cuse the lack of a post ref.) in greater depth on what follows. My take is, that the critical issue, alongside cash flow, is that time IS being allowed to pass by and no new drugs move in the pipeline. We have drug pipeline constipation. The opportunity cost of making management decisions which have a consequence of, say, Fungoff being delayed from coming to market one year sooner is NOT the first years profits (which may be minimal). Rather, it is the FINAL year's profits, viz., the year just before the drug loses it patent protection to generic competition. It is a bewildering state of afffairs.
To paraphrase you, Jim, let's call it Onetrickpony Sales Corp. Fox. |
